Servier Outlines M&A Strategy Amid Major Acquisitions
French pharmaceutical company Servier has completed several major acquisitions in 2026, including Day One Biopharmaceuticals for $2.5 billion and Edgewise Therapeutics' muscular dystrophy business for around $2.65 billion. The firm is also engaging in AI-focused deals with InSilico Medicine and Iktos as it navigates evolving global industry trends.
Tickers: $EWTX
Topics: AI in Healthcare M&A Pharmaceuticals Strategic Planning